Summary
No provided claim is supported by the supplied FDA label text, which appears to describe insulin lispro (and insulin lispro protamine/mix) rather than insulin glargine or insulin glargine biosimilars. Medication-specific efficacy/dosing/safety statements for insulin glargine cannot be verified.
Category Scores
Accurate Statements
Unsupported Statements
Insulin glargine is a long-acting insulin analog that provides a basal level of insulin for approximately 24 hours.
No insulin glargine-specific description or pharmacokinetics/duration language is present in the provided label sections (which appear to be for insulin lispro products).
Insulin glargine is designed to mimic the body's natural basal insulin secretion.
No insulin glargine mechanism/mimic language is present in the provided label sections.
Insulin glargine has a slightly different molecular structure than human insulin.
The provided structural difference language in 11 DESCRIPTION pertains to insulin lispro, not insulin glargine (insulin glargine structural claim is not supported as written).
After injection into the subcutaneous tissue, insulin glargine precipitates into microcrystals.
No insulin glargine precipitation/microcrystal language is present in the provided label sections.
Precipitation leads to a slow and continuous release of active insulin glargine into the bloodstream over an extended period.
No insulin glargine precipitation/release mechanism language is present in the provided label sections.
Slow and continuous release of insulin glargine reduces glucose levels.
While the label includes general insulin glucose-lowering activity, it does not provide the specific insulin glargine release mechanism or a supported insulin glargine-specific statement tying that mechanism to glucose reduction.
Insulin glargine is available in different concentrations and formulations.
No insulin glargine concentration/formulation information is present in the provided label sections (3 DOSAGE FORMS AND STRENGTHS is for insulin lispro products).
U-100 insulin glargine provides 100 units of insulin per milliliter.
No insulin glargine U-100 concentration language is present; the available U-100 (100 units/mL) strength shown is for insulin lispro protamine/lispro products.
Higher concentrations of insulin glargine, such as U-300 (Toujeo), are available.
No insulin glargine U-300/Toujeo information is present in the provided label sections.
U-300 insulin glargine offers a more concentrated option for patients who require higher doses.
No insulin glargine U-300 concentration/dosing rationale language is present in the provided label sections.
Insulin glargine formulations are often delivered via pre-filled pens for ease of use.
No insulin glargine device/pen delivery information is present in the provided label sections; the pen information is for insulin lispro products.
Original patents for Lantus began expiring in key markets around 2015-2016.
No patent/exclusivity/market timeline content is present in the provided label sections.
Patent strategies... have led to extended periods of market protection for some insulin glargine products.
No patent/market protection content is present in the provided label sections.
Biosimilar insulin glargine products are highly similar to their reference branded products.
No biosimilar insulin glargine similarity language is present in the provided label sections.
There are no clinically meaningful differences between biosimilar insulin glargine and reference products in terms of safety.
No biosimilar comparison/safety language is present in the provided label sections.
There are no clinically meaningful differences between biosimilar insulin glargine and reference products in terms of purity.
No biosimilar comparison/purity language is present in the provided label sections.
There are no clinically meaningful differences between biosimilar insulin glargine and reference products in terms of potency.
No biosimilar comparison/potency language is present in the provided label sections.
Biosimilar insulin glargine products offer a more affordable alternative once patent exclusivity for the originator drug has ended.
No pricing/exclusivity affordability statements are present in the provided label sections.
Several biosimilars have entered the market in various regions, increasing competition.
No market/competition statements are present in the provided label sections.
Sanofi is the originator of Lantus.
No company/originator statements are present in the provided label sections.
Following patent expiries, other pharmaceutical companies have developed and launched their own biosimilar versions of insulin glargine.
No patent expiry/biosimilar launch statements are present in the provided label sections.
Major players in the biosimilar insulin glargine space include Eli Lilly and Company (Basaglar).
No company/product market statements are present in the provided label sections.
Major players in the biosimilar insulin glargine space include Biocon.
No company/product market statements are present in the provided label sections.
The global insulin glargine market is influenced by the increasing prevalence of diabetes worldwide.
No epidemiology/market demand statements are present in the provided label sections.
Branded insulin glargine may face pressure from biosimilar competition and newer insulin formulations.
No market competition statements are present in the provided label sections.
Overall demand for long-acting insulin remains robust.
No market demand statements are present in the provided label sections.
Growth in insulin glargine demand is supported by advancements in delivery technologies.
No market growth statements or delivery technology statements are present in the provided label sections.
Growth in insulin glargine demand is supported by wider accessibility in developing economies.
No market accessibility statements are present in the provided label sections.
The most common side effect of insulin glargine is hypoglycemia (low blood sugar).
Provided hypoglycemia language is for insulin lispro protamine and insulin lispro mix, not insulin glargine.
Hypoglycemia with insulin glargine can occur if the dose is too high.
No insulin glargine-specific dosing-trigger phrasing is present in the provided label sections.
Hypoglycemia with insulin glargine can occur if meals are skipped.
No insulin glargine meal-skipping specific statement is present in the provided label sections.
Hypoglycemia with insulin glargine can occur if physical activity is increased unexpectedly.
No insulin glargine unexpected physical activity specific statement is present in the provided label sections.
Other potential side effects of insulin glargine include injection site reactions.
No injection-site reaction language for insulin glargine is present in the provided label sections.
Other potential side effects of insulin glargine include lipodystrophy (changes in fat tissue at the injection site).
No lipodystrophy language for insulin glargine is present in the provided label sections.
Other potential side effects of insulin glargine include allergic reactions.
While hypersensitivity is listed for the provided insulin lispro product, the label evidence provided does not support this generalized insulin glargine adverse reaction framing.
Insulin glargine is one of several long-acting insulin analogs available.
No inventory/comparative statement for insulin glargine and long-acting analogs is present in the provided label sections.
Insulin glargine is often compared to insulin detemir (Levemir) and insulin degludec (Tresiba).
No such comparisons are present in the provided label sections.
Insulin glargine U-100 typically lasts up to 24 hours.
No insulin glargine duration information is present in the provided label sections.
Insulin glargine U-300 offers a longer duration of action.
No insulin glargine U-300 duration information is present in the provided label sections.
Insulin degludec has an ultra-long duration of action, exceeding 42 hours.
No insulin degludec information is present in the provided label sections.
The choice between long-acting insulins depends on individual patient needs, lifestyle, and physician recommendation.
The provided label contains individualized dosage adjustment for insulin lispro mix products, but does not support a general statement about choosing between long-acting insulins based on lifestyle/physician recommendation for insulin glargine.
Branded insulin glargine tends to be more expensive than its biosimilar counterparts.
No pricing comparison statements are present in the provided label sections.
Many insurance plans cover both branded and biosimilar insulin glargine.
No payer/coverage statements are present in the provided label sections.
Formulary placement and prior authorization requirements for insulin glargine can differ.
No formulary/prior authorization statements are present in the provided label sections.
Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) oversee the approval of insulin glargine products and their biosimilars.
No regulatory oversight statements are present in the provided label sections.
For approval of biosimilars, sponsors must demonstrate a high degree of similarity to the reference product.
No biosimilar approval requirements are present in the provided label sections.
For biosimilar approval, differences from the reference product must not be clinically significant in safety.
No biosimilar approval requirements are present in the provided label sections.
For biosimilar approval, differences from the reference product must not be clinically significant in efficacy.
No biosimilar approval requirements are present in the provided label sections.
For biosimilar approval, differences from the reference product must not be clinically significant in immunogenicity.
No biosimilar approval requirements are present in the provided label sections.
Contradictions
Important Omissions
Insulin glargine-specific indications, dosage/administration, contraindications, warnings/precautions, adverse reactions, and other safety content cannot be verified because the provided label text appears to be for insulin lispro products rather than insulin glargine.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Many insulin glargine-specific efficacy/dosing/duration and safety claims are unsupported by the provided label text, which appears mismatched to the product claimed (insulin glargine vs insulin lispro products).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Provided label sections do not correspond to insulin glargine or insulin glargine biosimilars; extracted claims are largely unsupported.
Suggested Improvement
Use the correct FDA-approved prescribing information for insulin glargine (and its biosimilars) matching the claimed product; restrict claims to statements explicitly supported by the corresponding label sections (indications, dosing, contraindications, warnings/precautions, and adverse reactions).